HCC - HEPATOCELLULAR CARCINOMA

This study tests whether adding a targeted procedure (like chemoembolization) to standard immunotherapy and anti-VEGF drugs can better shrink tumors in people with advanced liver cancer. About 300 adults with BCLC stage B or C liver cancer will be split into two groups: one gets …

This study tests a new drug called AST-3424 for people with a specific type of advanced liver cancer that has gotten worse after immunotherapy. The trial compares AST-3424 to another standard drug, regorafenib, to see which helps people live longer. About 75 participants will rec…

This study tests a combination of four drugs (ipilimumab, sintilimab, bevacizumab biosimilar, and chemotherapy into the liver artery) in 43 adults with advanced liver cancer that cannot be removed by surgery. The goal is to shrink the tumors enough so that surgery becomes possibl…

This early-phase study tests a new drug called TGI-5, either alone or combined with the immunotherapy nivolumab, in people with advanced solid tumors (colorectal, melanoma, liver, or lung cancer) that cannot be removed by surgery. The main goals are to check safety and find the r…

This study tests a new treatment called INT001 for adults with liver cancer who cannot have surgery. Doctors inject the drug directly into the tumor using a needle guided by imaging. The goal is to see if it can completely destroy the tumor and what side effects occur. Participan…

This study tests a new treatment for people with advanced liver cancer that cannot be removed by surgery. It combines precise proton radiation with two immunotherapy drugs (tremelimumab and durvalumab) to boost the immune system's attack on tumors. About 45 participants will rece…

This early-stage trial tests a new drug called GV20-0251 in people with advanced solid tumors that no longer respond to standard treatments. The main goal is to check the drug's safety. About 10 adults with cancers like liver, lung, or skin cancer will take part. This is not a cu…

This study tests a combination of an experimental drug (CVM-1118), an immunotherapy (sintilimab), and a procedure that blocks the tumor's blood supply (TACE) in people with liver cancer that cannot be cured but hasn't spread. About 40 adults will receive all three treatments to s…

This pilot study tests a new approach for people with inoperable liver cancer. The goal is to shrink tumors using a combination of immunotherapy and targeted radiation, so that surgery to remove the cancer becomes possible. The study will enroll 30 participants and measure how ma…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors (like lung, head and neck, or colon cancer) that have stopped responding to standard therapies. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participant…

This study tests a new way of giving two cancer drugs (bevacizumab and atezolizumab) to people with advanced liver cancer who also have fatty liver disease. Instead of giving both drugs together, researchers want to see if giving them one after the other works better. The study w…

This study tests a new type of PET/CT scan that uses a special tracer to see if it can find liver cancer more accurately. About 40 adults with newly diagnosed or suspected returning liver cancer will get this scan. The goal is to improve how doctors detect and monitor the disease…

This study compares a newer, more detailed CT scan (spectral CT) with a standard CT scan to see which one better finds any leftover cancer after a liver tumor treatment called TACE. About 250 adults with liver cancer will get both scans after their TACE procedure. The goal is to …

This study looks at how radiation therapy affects tumor DNA that floats in the blood of people with liver cancer. Researchers want to see if changes in this DNA can help doctors know if the treatment is working, without waiting for scans. The study will involve 15 adults with liv…